NK cells promote transplant tolerance by killing donor antigen-presenting cells by Yu, Guang et al.
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BRIEF DEFINITIVE REPORT
NK cells are a major cell type in the innate 
immune system (1). Unlike T cells in the 
adaptive system, the innate NK cells are pro-
grammed to kill targets without prior antigen 
priming (1). The cytolytic activity of NK cells 
is tightly controlled by a group of cell surface 
receptors that can deliver either stimulatory 
or inhibitory signals, and engagement of in-
hibitory receptors by the self-MHC class I 
molecules is a principal mechanism by which 
NK-mediated damage to self is prevented (2, 3). 
However, NK cells are highly cytotoxic to 
target cells mismatched for the MHC class I 
molecules (4, 5) or autologous cells with 
down-regulated expression of self-MHC class 
I molecules (missing self theory) (3, 5). Thus, 
NK cells often function as potent eff  ector 
cells in rejection of allogeneic bone marrow 
cells (6) and solid organ transplants (7, 8). In 
certain models, however, NK cells also  express 
potent immunoregulatory properties that 
promote transplant tolerance (9), but the 
mechanisms are poorly defi  ned. A key ques-
tion that remains to be answered is how the 
innate cells would regulate the adaptive T cell 
response in transplant models, especially in 
tolerance induction.
Unlike any other models, priming of 
T cells for the rejection response in transplant 
models is induced primarily by the graft-
  derived donor APCs (i.e., direct antigen pre-
sentation), albeit host APCs with processed 
allogeneic peptides (indirect pathway) also 
contribute to the rejection response (10). This 
is because of the presence of large numbers of 
donor APCs normally residing in transplanted 
organs. It is well known that priming by the 
direct pathway often activates an unusually 
large mass of alloreactive T cell clones, which 
constitutes one of the potent barriers to the in-
duction of transplant tolerance (11). As the 
presence of host secondary lymphoid organs 
(e.g., spleen and lymph nodes) is mandatory for 
direct T cell priming and acute allograft rejec-
tion (12, 13), we hypothesized that survival 
and dissemination of graft-derived donor APCs 
in transplant recipients may critically aff  ect the 
nature of the rejection response and the suscep-
tibility to tolerance induction. In the present 
study, we found that host NK cells play a 
critical role in regulating the life and death of 
  donor-derived APCs, thereby aff  ecting the 
  locations and pathways of T cell priming in 
transplant tolerance induction.
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Natural killer (NK) cells are programmed to kill target cells without prior antigen priming. 
Because of their potent cytolytic activities, NK cells are one of the key cell types involved 
in dismantling allografts. However, in certain transplant models, NK cells also express 
potent immunoregulatory properties that promote tolerance induction. The precise mecha-
nism for such striking dichotomy remains unknown. In the present study, we showed in a 
skin transplant model that the skin allografts contain a subset of antigen-presenting cells 
(APCs) that can home to the recipient mice. We also showed that such graft-derived APCs 
are usually destroyed by the host NK cells. But in the absence of NK cells, donor APCs can 
survive and then migrate to the host lymphoid and extralymphoid sites where they directly 
stimulate the activation of alloreactive T cells. T cells activated in the absence of NK cells 
are more resistant to costimulatory blockade treatment, and under such conditions stable 
skin allograft survival is diffi  cult to achieve. Our study identifi  ed a novel role for NK cells 
in regulating T cell priming in transplant models, and may have important clinical implica-
tions in tolerance induction.
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(A) Staining for NK cells in Rag−/− and Rag−/−γc−/− mice. Cells were prepared 
from the spleen (Sp), liver (Lv), and lungs (Lg) of Rag−/− and Rag−/−γc−/− 
mice and examined for the presence of NK1.1+ cells. Data from four indi-
vidual experiments are shown. (B) Long-term survival of DBA/2 skin allografts 
transplanted onto Rag−/− and Rag−/−γc−/− mice. Pictures shown are rep-
resentative of skin allografts and tissue histology at 200 d after transplan-
tation. (C) Analysis of graft-derived donor cells in Rag−/− and Rag−/−γc−/− 
mice transplanted with DBA/2 skin allografts. Spleen cells were prepared 
from the Rag−/− and Rag−/−γc−/− mice 30 d after grafting with DBA/2 
skin allografts. The spleen cells were then stained with PE anti–H-2Dd mAb 
to determine the presence or absence of donor-derived cells. Representative 
data of three individual experiments are shown. (D) Survival and dissemina-
tion of allogeneic donor DCs in Rag−/− and Rag−/−γc−/− hosts. MACS 
sorted CD11c+ DCs from DBA/2 donors were injected into Rag−/− and 
Rag−/−γc−/− recipients. 2 wk later, the host mice were killed and cells were 
prepared from the spleen (Sp), liver (Lv), and lungs (Lg), followed by staining 
with PE anti–H-2Dd mAb to determine donor-origin cells. Representative 
plot of four individual experiments is shown. (E) Survival of (DBA/2 x B6)F1 
DCs but not DBA/2 DCs in Rag−/− hosts.
RESULTS AND D  I  S  C  U  S  S  I  O  N 
To defi  nitively determine the role of NK cells in transplant 
models, we transplanted the DBA/2 skin allografts (H-2d) 
onto the Rag defi  cient (Rag−/−) and Rag plus the common 
γc double-defi  cient mice (Rag−/−γc−/−) (H-2b), and exam-
ined the skin allograft survival and the fate of graft-derived 
APCs in the recipient mice. Both Rag−/− and Rag−/−γc−/− 
mice are defi   cient for T cells and B cells. Unlike the 
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Rag−/−γc−/− mice, which are also defi  cient for NK cells 
(14), the Rag−/− mice have a large population of NK cells in 
the periphery (Fig. 1 A). Thus, the eff  ects of NK cells against 
the DBA/2 skin allografts and their residing donor APCs can 
be directly studied.
Both Rag−/− and Rag−/−γc−/− mice permanently ac-
cepted the DBA/2 skin allografts (>200 d, n = 5) without 
any gross or histological signs of rejection (Fig. 1 B). How-
ever, the fate of graft-derived donor APCs in the Rag−/− 
and Rag−/−γc−/− hosts was strikingly diff   erent. In the 
Rag−/−γc−/− mice, donor APCs could be readily identi-
fi  ed in the host spleen. Such graft-derived cells included 
CD11c+ DCs (Fig. 1 C), a cell type that undoubtedly con-
tributes to the high immunogenicity of the skin grafts 
(15). In contrast, such donor APCs were completely absent 
in the Rag−/− hosts. This striking difference concerning 
the presence or absence of donor APCs in Rag−/− and 
Rag−/−γc−/− mice persisted for a long period of time after 
skin transplantation (30–100 d later). This fi  nding suggests 
that NK cells may play a particularly important role in re-
gulating the survival and dissemination of donor APCs in 
transplant recipients.
To further address this issue, we purifi  ed CD11c+ DCs 
from DBA/2 donors and adoptively transferred them into 
Rag−/− and Rag−/−γc−/− mice ( 6 × 106 DCs/mouse). 
Survival and dissemination of the allogeneic DCs in the host 
mice was determined 2 wk later. As shown in Fig. 1 D, 
DBA/2 DCs were completely destroyed upon transferring 
into the Rag−/− mice, and such cells could no longer be 
found in either the spleen or the extralymphoid tissues (i.e., 
liver and lungs). In sharp contrast, the allogeneic DBA/2 DCs 
could be readily recovered from the spleen of Rag−/−γc−/− 
mice. Importantly, such allogeneic DCs also accumulated in 
large numbers in the extralymphoid organs in Rag−/−γc−/− 
hosts (Fig. 1 D). Destruction of allogeneic DCs is mediated 
primarily by host NK cells as DCs from (DBA/2 x B6) F1 
mice survived well in the Rag−/− mice (Fig. 1 E). Hence, 
the presence or absence of NK cells can have a profound 
  impact on life and death of fully MHC mismatched donor 
APCs in vivo.
To determine whether the donor DCs homing to the 
host mice could stimulate the activation of alloreactive T 
cells, we again purifi  ed DCs from DBA/2 mice and trans-
ferred them into Rag−/− and Rag−/−γc−/− mice. 2 wk 
later, the host mice were reconstituted with CFSE-labeled 
syngeneic C57BL/6 T cells ( 20 × 106/mouse). Prolifera-
tion of syngeneic T cells in diff  erent compartments of the 
host mice was examined 3 d later. As shown in Fig. 2 A, the 
adoptively transferred T cells readily accumulated in both 
Figure 2.  T cell activation in vivo with or without NK cells. 
(A) Proliferation of T cells adoptively transferred into Rag−/− and Rag−/−γc−/− 
mice injected with allogeneic DBA/2 DCs. CD11c+ DCs prepared from 
DBA/2 donors were injected into Rag−/− and Rag−/−γc−/− recipients 
( 6 × 106 DCs per mouse). 2 wk later, each mouse was reconstituted 
with  20 × 106 CFSE-labeled syngeneic C57BL/6 T cells. Proliferation of 
T cells in the host spleen, liver, and lungs was determined 3 d later by 
gating onto the CD3+ fraction. Similar data were obtained in four inde-
pendent experiments. (B) Proliferation of T cells adoptively transferred 
into Rag−/− and Rag−/−γc−/− mice without injection of allogeneic DCs. 
CFSE-labeled syngeneic T cells were transferred into Rag−/− and Rag−/−γc−/− 
mice (20 × 106 cells per mouse) and analyzed 3 d later by gating onto 
the CD3+ fraction. Similar data were obtained in three individual experi-
ments. (C) Production of IFN-γ by T cells transferred into Rag−/− and 
Rag−/−γc−/− mice injected with allogeneic DBA/2 DCs. CD11c+ DCs from 
DBA/2 donors were injected into Rag−/− and Rag−/−γc−/− mouse. 
2 wk later, each mouse was reconstituted with  20 × 106 CFSE-labeled 
syngeneic C57BL/6 T cells. T cells were isolated from the host spleen 3 d 
later and restimulated ex vivo with donor DBA/2 cells for 24 h, and pro-
duction of IFN-γ was determined by ELISPOT. Data are presented as 
mean ± SD spots of triplicate assays. *P < 0.05.
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Figure 3.  Effect of costimulatory blockade on T cell activation in 
vivo in the absence of NK cells. (A) Recovery of transferred T cells from 
Rag−/−γc−/− mice injected with allogeneic DBA/2 DCs and treated with 
CD28/CD154/OX40 costimulatory blockade. CD11c+ DCs from DBA/2 do-
nors were injected into Rag−/−γc−/− hosts. 2 wk later, each mouse was 
reconstituted with  20 × 106 CFSE-labeled syngeneic C57BL/6 T cells. 
Some Rag−/−γc−/− hosts were also treated with CD28/CD154/OX40 
blockade protocol. Recovery of CD3+ T cells in the host spleen, liver, and 
lungs was determined 3 d later. Representative data of three individual 
experiments are shown. (B) Effect of blocking CD28/CD154/OX40 
costimulation on proliferation of adoptively transferred T cells in 
Rag−/−γc−/− mice injected with allogeneic DBA/2 DCs. The Rag−/−γc−/− 
mice were prepared as described in Fig. 3 A, and proliferation of T cells 
at different sites of Rag−/−γc−/− mice was determined 3 d later by 
gating onto the CD3+ fraction. Representative data of three individual 
experiments are shown.JEM VOL. 203, August 7, 2006  1855
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the spleen and the extralymphoid organs in Rag−/−γc−/− 
hosts. In the Rag−/− mice, however, such T cells primarily 
accumulated in the spleen but not in the extralymphoid 
organs. Analysis of their CFSE profi  le revealed that most of 
the T cells recovered from the Rag−/− mice did not enter 
the cell cycle and, therefore, remained undivided (Fig. 2 A). 
In contrast, T cells from the Rag−/−γc−/− mice divided 
vigorously, and multiple rounds of cell divisions could 
be clearly identifi   ed. Such   vigorous T cell division in 
Rag−/−γc−/− mice was observed not only in the spleen but 
also in the extralymphoid sites. Adoptive transfer of synge-
neic T cells only ( 20 × 106/mouse) into Rag−/− and 
Rag−/−γc−/− mice without donor DCs did not induce 
marked T cell proliferation in vivo (Fig. 2 B). Thus, the 
large number of T cells injected ( 20 × 106/mouse) and 
the time point examined (only 3 d) did not   induce homeo-
static proliferation (16); and T cell proliferation in this model 
is induced primarily by donor DCs.
To further examine the eff  ector functions of T cells trans-
ferred into Rag−/− and Rag−/−γc−/− mice with or without 
prior injection of allogeneic DCs, T cells were recovered 
from the host mice 3 d later and restimulated ex vivo with 
donor antigens and production of IFN-γ was assessed by 
ELISPOT assay. As shown in Fig. 2 C, T cells recovered 
from Rag−/− and Rag−/−γc−/− mice without prior injection 
of donor DCs did not produce detectable levels of IFN-γ. In 
contrast, T cells recovered from Rag−/−γc−/− mice injected 
with donor DCs readily produced a copious amount of IFN-γ 
( 400 spots/200,000 T cells), which was  8 times higher 
than those from Rag−/− mice ( 50 spots/200,000 T cells). 
Similar fi  ndings were observed for T cells recovered from the 
liver and the lungs (unpublished data). These fi  ndings strongly 
suggest that, in the absence of NK cells, the injected alloge-
neic DCs survived and then migrated to the host spleen and 
extralymphoid sites where they directly stimulated the activa-
tion and eff  ector function of alloreactive T cells.
Clearly, NK cells have a profound impact on life and 
death of donor APCs in transplant recipients. To determine 
the activation requirement of T cells stimulated by the donor 
DCs in the host mice, we reconstituted the Rag−/−γc−/− 
mice with CFSE-labeled syngeneic T cells 2 wk after injec-
tion of allogeneic DBA/2 DCs. The host mice were then 
treated with CTLA-4Ig, anti-CD154, and anti-OX40L to 
transiently block CD28/CD154/OX40 costimulatory path-
ways (triple costimulatory blockade), and proliferation of 
T cells in the Rag−/−γc−/− mice was examined 3 d later. As 
shown in Fig. 3 A, treatment of host mice with CD28/
CD154/OX40 costimulatory blockade protocol resulted in 
a marked reduction of T cell recovery compared with un-
treated controls, suggesting that blocking CD28/CD154/
OX40 costimulatory pathways may inhibit T cell prolifera-
tion and/or their survival (17). However, among the T cells 
recovered from the treated Rag−/−γc−/− mice, a subset of 
T cells still proliferated in the spleen and in the extralym-
phoid sites (Fig. 3 B). Moreover, most of the T cells recov-
ered from the extralymphoid organs had divided for multiple 
times despite CD28/CD154/OX40 blockade treatment (Fig. 
3 B). Thus, priming of T cells in vivo by the donor APCs is 
more resistant to CD28/CD154/OX40 blockade treatment 
in the absence of NK cells.
Our data suggest that in models where NK cells are im-
paired or depleted, transplant tolerance to MHC mismatched 
allografts would be diffi   cult to achieve. To test this possibility 
in a stringent model, we grafted the full-thickness DBA/2 
(H-2d) skin allografts onto the highly resistant C57BL/6 
(H-2b) recipients (18). The recipient mice were treated with 
CD28/CD154/OX40 costimulatory blockade with or with-
out NK depletion, and graft survival was determined. As 
shown in Fig. 4 A, C57BL/6 mice readily rejected the
DBA/2 skin allografts with a mean survival time (MST) of 8 d 
(n = 7). Treatment of C57BL/6 mice with transient CD28/
CD154/OX40 costimulatory blockade enabled long-term 
skin allograft survival, and all the DBA/2 skin allografts sur-
vived for >100 d (n = 13). Interestingly, depletion of NK 
cells from the recipient mice using a depleting anti-NK1.1 
mAb rendered the triple costimulatory blockade protocol 
completely ineff  ective at preventing the rejection response, 
and all NK-depleted and triple blockade–treated mice re-
jected the DBA/2 skin allografts with a MST of 22 d (n = 8). 
This was in striking contrast to triple blockade–treated mice 
without NK depletion in which all the DBA/2 skin allografts 
survived for >100 d.
As shown in Fig. 4 B, transplantation of DBA/2 skin 
  allografts onto CD1d KO mice (NKT defi  cient)  induced 
prompt skin allograft rejection (MST = 8 d, n = 5). Similar 
to the WT C57BL/6 controls, treatment of the CD1d KO 
recipients with the triple costimulatory blockade protocol 
markedly prolonged the skin allograft survival (MST > 50 d, 
n = 5). Interestingly, depletion of NK cells from the triple 
blockade–treated CD1d KO mice precipitated rapid rejec-
tion of the DBA/2 skin allografts (MST = 23 d, n = 4). This 
fi  nding suggests that NK cells, but not NKT cells, are critical 
to stable skin engraftment in this model.
To ascertain that the requirement for NK cells to enable 
skin allograft survival is confi   ned to MHC mismatched 
transplants, we transplanted both DBA/2 (H-2d) and 129/svJ 
(H-2b) skin allografts onto the same C57BL/6 recipients 
(H-2b) with or without triple costimulatory blockade and 
NK depletion. As shown in Fig. 4 C, C57BL/6 mice 
promptly rejected both the DBA/2 skin grafts (MST = 8 d, 
n = 6) and the multiple minor antigen-mismatched 129/svJ 
skin grafts (MST = 9 d, n = 6). Treatment of recipient mice 
with CD28/CD154/OX40 costimulatory blockade induced 
uniform long-term survival of both DBA/2 and 129/svJ 
skin allografts in the same recipients (MST > 100 d, n = 6). 
Depletion of NK cells in the triple blockade–treated mice 
precipitated prompt rejection of the DBA/2 skin allografts 
(MST = 18 d, n = 6), but survival of the 129/svJ skin 
allograft was not aff  ected (MST > 100 d, n = 6) (Fig. 4 D). 
Furthermore, T cells were isolated from C57BL/6 mice that 
were grafted with DBA/2 skin allografts and treated with 
the triple costimulatory blockade protocol with or without 1856  INNATE NK CELLS IN ALLOGRAFT TOLERANCE | Yu et al. 
Figure 4.  Critical requirement of NK cells in allograft survival. 
(A) Role of NK cells in CD28/CD154/OX40 costimulatory blockade induced 
skin allograft survival. C57BL/6 mice were grafted with DBA/2 skin allo-
grafts and treated with CTLA4-Ig, anti-CD154, and anti-OX40L. A cohort 
of recipients was also treated with anti-NK1.1 mAb to deplete NK cells in 
addition to CD28/CD154/OX40 costimulatory blockade. The skin allograft 
survival was presented in a Kaplan-Meier plot. *P < 0.05. (B) Skin allograft 
survival in NKT-defi  cient mice treated with CD28/CD154/OX40 costimula-
tory blockade protocol with or without NK depletion. (C) Effect of blocking 
CD28/CD154/OX40 pathways on survival of DBA/2 and 129/svJ skin allo-
grafts transplanted onto the same C57BL/6 recipients. DBA/2 and 129/svJ 
skin grafts were transplanted onto the C57BL/6 recipients. Groups of re-
cipient mice were treated with CD28/CD154/OX40 blockade protocol. Skin 
allograft survival was presented in a Kaplan-Meier plot. The picture shows 
healthy skin allografts 100 d after transplantation. (D) Differential require-
ment of NK cells in survival of DBA/2 and 129/svJ skin allografts induced 
by CD28/CD154/OX40 costimulatory blockade. C57BL/6 mice were grafted 
with DBA/2 and 129/svJ skin allografts and treated with CD28/CD154/
OX40 blockade protocol. The recipient mice were also treated with a 
  depleting anti-NK1.1 mAb in addition to CD28/CD154/OX40 blockade 
treatment. Skin allograft survival was presented in a Kaplan-Meier plot. 
(E) Enhanced T cell priming in vivo in C57BL/6 recipients depleted of NK 
cells. C57BL/6 mice were grafted with DBA/2 skin allografts and treated 
with CD28/CD154/OX40 blockade protocol with or without NK depletion. 
10 d later, T cells from the host spleen were prepared and stimulated in 
vitro with mitomycin C–treated donor DBA/2 spleen cells; cell proliferation 
was determined 3 d later by 3H-TdR uptake assay. Data are presented as 
mean cpm ± SD of triplicate assays. *P < 0.05.
NK depletion. The isolated T cells were rechallenged 
ex vivo with mitomycin C–treated donor DBA/2 cells, and 
cell proliferation was determined 3 d later by 3H-TdR up-
take assay. As shown in Fig. 4 E, T cells from NK-depleted 
mice displayed enhanced proliferation compared with those 
without NK depletion, further confi  rming that depletion of 
NK cells resulted in amplifi  ed T cell priming in vivo by the 
donor antigens.
Here we have identifi  ed a novel role for NK cells in regu-
lating the adaptive T cell response in transplant models. In con-
trast to the traditional belief, the cytolytic NK cells are an 
indispensable cell type for the induction of skin allograft sur-
vival. A key role for NK cells in our model appears to control 
the survival and dissemination of graft-derived donor APCs in 
transplant recipients, thereby containing the locations and path-
ways of antigen presentation and the size of alloreactive T cell JEM VOL. 203, August 7, 2006  1857
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clones. Thus, for the highly immunogenic transplants, like the 
skin where DCs are present in large numbers (15), NK-mediated 
destruction of certain graft-derived APCs may be one of the 
critical steps in the acquisition of transplant tolerance.
Our study has several important implications. First, in 
transplant models, donor-derived APCs can readily accumu-
late at multiple sites in transplant recipients when NK cells 
are absent or depleted. As the identity of T cells accumulating 
at the extralymphoid organs is often diff  erent from that in the 
lymphoid tissues (19), T cell priming at these sites may be an 
important mechanism of tolerance resistance. However, it 
remains unclear whether the cytolytic activity of NK cells 
against donor-derived APCs is mediated by all NK cells or is 
confi  ned to a specifi  c NK subset. Equally important is the 
  issue as to whether all kinds of donor APCs are sensitive to 
NK-mediated killing or diff  erent cell types are distinct. Sec-
ond, despite their potent cytolytic activities, NK cells by 
themselves do not cause damage to the skin allografts. It is 
well known that NK cells express both stimulatory and in-
hibitory cell surface receptors (2), and the balanced acts of 
such positive and negative signals dictate the cytolytic func-
tion of NK cells (2). In this regard, our model may provide a 
valuable tool to further examine whether parenchymal tissues 
and hematopoietic cells diff  erentially express novel stimula-
tory or inhibitory ligands for the NK receptors. Finally, our 
new fi  ndings suggest that in solid organ transplantation, ther-
apies that interfere with NK cell function or induce NK tol-
erance may hinder the induction of tolerance by facilitating 
the survival and dissemination of donor APCs. Thus, strat-
egies to selectively modulate the cytolytic activities of NK 
cells may be important in the induction of allograft tolerance, 
especially to highly immunogenic transplants.
MATERIALS AND METHODS
Animals. DBA/2 (H-2d), C57BL/6 (H-2b), Rag1−/− (H-2b), and 129/SvJ 
(H-2b) mice were purchased from The Jackson Laboratory. Rag2−/−γc−/− 
double mutant mice (H-2b) were obtained from the Taconic Farm 
  (Germantown, New York). CD1d KO mice on the B6 background (H-2b) 
were provided by M. Exley (Beth Israel Deaconess Medical Center, Boston, 
MA). Animal use and care conformed to the guidelines established by the 
Animal Care Committee at Harvard Medical School in Boston, MA.
Reagents. The following anti–mouse mAbs were purchased from BD 
  Biosciences: PE anti–mouse CD3 (clone 17A2), cychrome–anti-CD4 
(clone GK1.5), cychrome–anti-CD8α (clone 53–6.7), PE–anti–H-2Dd 
(clone 34–2-12), PE–anti-NK1.1 (clone PK136), and isotype control anti-
bodies. The anti–mouse IFN-γ capture antibody (clone R4-6A2), biotin 
anti–IFN-γ detection antibody (clone XMG1.2), and streptavidin-conju-
gated horseradish peroxidase for ELISPOT assays were also obtained from 
BD Biosciences.
A cell line producing human CTLA–4Ig fusion protein was purchased 
from the American Type Culture Collection, and the fusion protein was 
produced by BioExpress. Anti-CD154 mAb (clone MR1), anti-OX40 
  ligand (OX40L) mAb (clone RM134L), and anti-NK1.1 mAb (clone 
PK136) used for in vivo studies were manufactured from hybridoma lines by 
BioExpress and used as previously reported (17, 20).
CD11c+ DC preparation and adoptive transfer. DCs from donor DBA/2 
mice were prepared as previously described (21). In brief, CMS-5 cells trans-
fected with the mouse Flt3-ligand gene were injected subcutaneously into 
DBA/2 mice (40 × 106 cells per mouse). This protocol consistently induces 
a large number of CD11c+ DCs in the host spleen (21). 10 d later, the mice 
were killed and total splenic cells were prepared. The spleen cells were then 
labeled with anti-CD11c–conjugated  MicroBeads (Miltenyi Biotec), and 
CD11c+ DCs were positively isolated using the magnetic-assisted cell sorting 
(Miltenyi Biotec) according to manufacturer’s instructions. The purity of DCs 
isolated using this method is consistently >90%. The highly purifi  ed DCs 
were adoptively transferred into Rag−/− and Rag−/−γc−/− mice via the tail 
vein, and 5–6 × 106 DCs were injected into each mouse for analyses.
T cell labeling with CFSE and adoptive transfer. C57BL/6 mice were 
killed, and single cell suspension was prepared from the spleen and peripheral 
lymph nodes. T cells were isolated from such cell preparation using the T cell 
enrichment columns (R&D Systems) according to the manufacturer’s in-
structions. The purity of T cells isolated using this method is >90% as con-
fi   rmed by FACS. The purifi   ed T cells were then labeled with CFSE 
(Molecular Probes) as previously reported (22). The CFSE-labeled T cells 
were washed twice in HBSS before i.v. injection into Rag−/− and Rag−/−γc−/− 
mice. For the in vivo assays, at least 20 × 106 T cells were injected into each 
mouse via the tail vein. In some experiments, the Rag−/− and Rag−/−γc−/− 
mice were injected with allogeneic DCs prepared from DBA/2 mice 2 wk 
  before reconstitution with CFSE-labeled syngeneic T cells.
In vivo CFSE assay. 3 d after injection of host mice with CFSE-labeled 
T cells, the host mice were killed, and spleen, liver, and lungs were har-
vested. Spleen cells were prepared as previously reported (23). For isolation 
of lymphoid cells from the liver and lungs, the organs were fi  rst perfused 
with 0.2% collagenase type IV (Worthington Biochemical Corporation) and 
then digested at 37
oC for 30 min. The digested tissues were disrupted by 
vigorous vortex, and the lymphoid cells were further isolated by Ficoll gradi-
ent centrifugation. The isolated lymphoid cells were resuspended in PBS 
containing 0.5% BSA and briefl  y stained with cychrome–anti–mouse CD3 
on ice for 15 min. After the staining, cells were washed, fi  xed in 1% formal-
dehyde, and analyzed by FACS.
Flow cytometry. All samples were analyzed using a FACSort equipped 
with CellQuest software (BD Biosciences) (23). Cells were electronically 
gated based on FCS and SSC parameters to exclude cell debris and dead 
cells. The phenotype and proliferation of gated cells were analyzed in de-
tails. For analysis of in vivo CFSE dilution assays, additional gate was set 
onto the CD3+ fraction, and the CFSE profi  les of CD3+ T cells were pre-
sented in histograms with the y axis being relative cell numbers. For pheno-
typic analysis of gated cells, specifi  c cell staining was presented in histograms 
or dot plots, and positive staining was calculated as the percentage of total 
cells gated.
ELISPOT assay. ELISPOT assay was performed to quantitate IFN-γ pro-
duction by activated T cells as we previously reported (20). In brief, Immuno-
Spot plates were coated with 4 μg/ml rat anti–mouse IFN-γ capture mAb 
(clone R4-6A2) at 4°C overnight. T cells were isolated from the host mice 
using MACS-assisted cell sorting (Miltenyi Biotec) and then placed in each 
well (2 × 105 cells/well) in the presence or absence of mitomycin C–treated 
allogeneic DBA/2 stimulators (8 × 105 cells/well). The plates were cultured 
in complete RPMI medium (10% FCS, 1% penicillin/streptomycin/ 
l-glutamine) at 37°C for 24 h. Cells were discarded from the plates, followed 
by washing in PBS containing 0.05% Tween-20. A biotinylated rat anti–
mouse IFN-γ detection mAb (clone XMG1.2) (0.5 μg/ml) was added in 
each well, followed by incubation at 4°C for overnight. The IFN-γ spots 
were developed using BD AEC substrate reagent set. The spots were then 
quantitated using a computer-assisted ELISPOT image analyzer (T Spot 
  Image Analyzer; Cellular Technology Ltd.).
Skin transplantation and treatment protocols. Full thickness tail skin 
grafts from donor mice were transplanted onto the thoracic wall of recipi-
ent mice as we reported before (17). Graft survival was assessed by daily 1858  INNATE NK CELLS IN ALLOGRAFT TOLERANCE | Yu et al. 
visual inspection, and rejection was defi  ned as the complete loss of viable 
tissue grafts.
Treatment of recipient mice with the triple costimulatory blockade 
  protocol consisted of CTLA-4Ig (0.5 mg, i.p. on days 1 and 3), anti-CD154 
(0.5 mg, i.p. on days 0, 1, 3, and 6), and anti-OX40L mAb (0.5 mg, i.p. on 
days 0, 2, 4, and 8). Day 0 is defi  ned as the time of skin transplantation.
NK depletion. Depletion of NK cells in vivo in transplant recipient mice 
was induced by i.p. injection of a depleting anti-NK1.1 mAb (clone PK136). 
The depleting mAb was given at 0.5 mg i.p. on days –2, 0, and 2 during skin 
grafting. This protocol has proven potency in depleting all the NK1.1+ cells 
in the periphery (9).
3H-TdR incorporation. C57BL/6 mice grafted with DBA/2 skin allograft 
were treated with CD28/CD154/OX40 costimulatory blockade protocol 
with or without NK cell depletion. 10 d later, the recipient mice were killed 
and spleen cells were prepared in complete RPMI 1640 medium supple-
mented with 10% FCS and 1% penicillin/streptomycin. Cells were then 
plated in 96-well tissue culture plates (2 × 105/well) and stimulated with 
  mitomycin C–treated donor DBA/2 spleen cells (4 × 105/well) in a fi  nal 
volume of 200 μl/well. Cells were cultured at 37°C for 3 d, and for the last 
16 h of culture, cells were pulsed with 1 μCi 3H-TdR/well (BD  Biosciences), 
and  3H-TdR uptake was determined by scintillation counting (Beckman 
  Instrument). Results are plotted as mean cpm ± SD of triplicate assays.
Statistics. Diff  erence in skin allograft survival was analyzed by log-rank test. 
Other data were compared using Student’s t tests. P < 0.05 was defi  ned 
as signifi  cant.
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